nanomaterials Review Use of Protamine in Nanopharmaceuticals—A Review Ivana Ruseska †, Katja Fresacher †, Christina Petschacher and Andreas Zimmer * Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, Karl-Franzens-University Graz, Universitätsplatz 1, 8010 Graz, Austria;
[email protected] (I.R.);
[email protected] (K.F.);
[email protected] (C.P.) * Correspondence:
[email protected] † Both authors are contributed equally. Abstract: Macromolecular biomolecules are currently dethroning classical small molecule therapeu- tics because of their improved targeting and delivery properties. Protamine-a small polycationic peptide-represents a promising candidate. In nature, it binds and protects DNA against degradation during spermatogenesis due to electrostatic interactions between the negatively charged DNA- phosphate backbone and the positively charged protamine. Researchers are mimicking this technique to develop innovative nanopharmaceutical drug delivery systems, incorporating protamine as a carrier for biologically active components such as DNA or RNA. The first part of this review high- lights ongoing investigations in the field of protamine-associated nanotechnology, discussing the self-assembling manufacturing process and nanoparticle engineering. Immune-modulating prop- erties of protamine are those that lead to the second key part, which is protamine in novel vaccine technologies. Protamine-based RNA delivery systems in vaccines (some belong to the new class of mRNA-vaccines) against infectious disease and their use in cancer treatment are reviewed, and we provide an update on the current state of latest developments with protamine as pharmaceutical Citation: Ruseska, I.; Fresacher, K.; excipient for vaccines. Petschacher, C.; Zimmer, A. Use of Protamine in Nanopharmaceuticals— Keywords: protamine; proticles; nanoparticles; novel vaccine technologies A Review.